There is currently an urgent need for effective COVID-19 drugs. High-throughput screening for drug discovery has been important in finding antiviral drugs focused on the spike protein 113 and the main protease (M pro ) 114 of SARS-CoV-2. However, computational structure-based drug discovery focused on immune system proteins is imperative to select potential drugs that, after being effectively analyzed in cell lines (i.e., African green monkey cells) and clinical trials, these can be considered for treatment of complex symptoms of COVID-19 patients. Drug repurposing offers a potentially rapid mechanism to deployment, since the safety profiles are known .